Tin tức & Cập nhật

Among patients with metastatic renal cell carcinoma (RCC) who have received first-line therapies, complete response rates are lower in the real-world population than in the clinical trial population, reports a recent study. Complete response predicts a favourable overall survival.

Mindfulness and cognitive behavioural therapy (CBT) appear beneficial for prostate cancer survivors and their partners who are dealing with sexual dysfunction, a study has shown.

A cost minimization analysis based on a literature review and Hong Kong data suggests that using subcutaneous (CS) instead of intravenous (IV) trastuzumab for HER2-positive breast cancer (BC) patients can offer an annual saving of more than USD 8.3 million to the Hong Kong healthcare system.

Genetic susceptibility to ovarian cancer does not appear to modify the protective association between frequent aspirin use and the risk of developing the cancer, as shown in a study.

Consumption of sugar-sweetened beverages and fruit juices does not seem to contribute to the risk of gastric cancer (GC), according to a prospective cohort study.

The adjuvant chemotherapy regimen epirubicin plus paclitaxel (EP) appears to be as good as the regimen that consists of epirubicin and cyclophosphamide followed by paclitaxel (EC-P) in the treatment of Asian women with operable ERBB2-negative breast cancer, according to the results of an open-label phase III trial.

Treatment with tyrosine kinase inhibitors (TKIs), such as sunitinib, provides survival benefits to patients with metastatic pheochromocytomas/paragangliomas (PPGLs), suggests a recent study.

In a post hoc analysis of two prospective studies, netupitant/palonosetron (NEPA) combined with dexamethasone has demonstrated similar efficacy vs a quadruplet regimen of olanzapine, aprepitant, ondansetron, and dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV) in Chinese women with early breast cancer (BC) receiving doxorubicin/cyclophosphamide (AC) in Hong Kong.

For patients with stage III or IV melanoma, treatment with pembrolizumab both before and after surgical resection leads to longer event-free survival than treatment with pembrolizumab only after the procedure, according to the results of a phase II study.